Physician profile
Deborah S Baker
NPI 1801982061
$1,253.32
in general payments reported to CMS, 2019-2025
19 companies · $57.37 in 2025
The $57.37 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.28 · 2022: $556 · 2023: $568 · 2024: $19.47 · 2025: $57.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $244.71 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $163.78 | 2022-2023 | Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $137.78 | 2022-2024 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $108.69 | 2022 | |
| Pfizer INC. | $104.58 | 2021-2023 | |
| Csl Behring | $97.65 | 2022-2023 | Hizentra, Haegarda |
| Octapharma USA, INC. | $53.39 | 2022-2023 | Cutaquig |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.01 | 2022-2023 | |
| Stryker Corporation | $36.90 | 2025 | Flowstasis, Inthrill Thrombectomy Catheter |
| Pharming Healthcare, INC. | $35.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $33.41 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.43 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $27.73 | 2022 | |
| Aimmune Therapeutics, INC. | $21.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.47 | 2025 | Caplyta |
| Kaleo, INC. | $18.98 | 2022 | |
| Biocryst US Sales Co., LLC | $15.91 | 2023 | Orladeyo |
| Amgen INC. | $11.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.